Selective Internal Radiotherapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment of Cholangiocellular Carcinoma (CCC).
Phase 2
- Conditions
- Intrahepatic Cholangiocellular Carcinoma
- Interventions
- Procedure: SIRTProcedure: DEB TACE
- Registration Number
- NCT01798147
- Lead Sponsor
- Johannes Gutenberg University Mainz
- Brief Summary
Selective Internal Radiotherapy is superior to Transarterial Chemoembolisation for the treatment of intrahepatic cholangiocellular carcinoma (CCC).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
- ≥18 years
- Intrahepatic CCC, proven by histology or by typical morphology in cross sectional imaging and elevated tumor markers (CEA or CA 19-9)
- Tumor confined to the liver
- At least one measurable lesion in magnetic resonance imaging (MRI)
- Tumor load ≤ 50%
- Preserved liver function (Child Pugh A and B)
- ECOG performance status ≤2
Exclusion Criteria
- Patients feasible for curative treatment (e.g. resection or local ablation)
- Previous TACE or SIRT
- Prior Chemotherapy
- Child Pugh stage C
- ECOG Performance Status >1
- Tumor involvement >50% of the liver
- Extrahepatic tumor
- Serum Bilirubin >2.0 mg/dl; Serum Albumin 2.8 g/dl, Serum Creatinine >2 mg/dl; Leukocytes <3000/ml; Thrombocytes <50000/ml
- Clinically apparent ascites (ascites only in CT/MRI is no exclusion criteria)
- Esophageal bleeding during the last 3 months
- Hepatic encephalopathy
- Transjugular intrahepatic portosystemic shunt (TIPS)
- Infiltration or occlusion of the main portal vein
- Hepatofugal blood flow in the portal vein
- Hepatopulmonary shunt ≥ 20% in the macroaggregated albumin scan (MAA-scan)
- Contraindications against angiography
- Pregnancy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description SIRT SIRT Selective Internal Radiotherapy using Yttrium 90 loaded resin beads (Sir Spheres) DEB TACE DEB TACE Drug eluting Beads (DC Beads) loaded with Doxorubicin
- Primary Outcome Measures
Name Time Method Progression-free survival (PFS) at the end of study
- Secondary Outcome Measures
Name Time Method Overall survival (OS) at the end of study Time to progression (TTP) at the end of study
Trial Locations
- Locations (1)
Department of Diagnostic and Interventional Radiology
🇩🇪Mainz, Germany